Pfizer Inc [NYSE: PFE] loss -0.74% on the last trading session, reaching $28.09 price per share at the time. If compared to the average trading volume of 30.76M shares, PFE reached a trading volume of 42452137 in the most recent trading day, which is why
Pfizer Inc. [NYSE: PFE] stock went on a downward path that fall over -0.66% on Friday, amounting to a one-week price decrease of less than -2.64%. Over the last 12 months, PFE stock dropped by -7.42%. The one-year Pfizer Inc. stock forecast points to a
Pfizer Inc. [NYSE: PFE] closed the trading session at $29.22. The stocks have a year to date performance of 1.49 percent and weekly performance of 0.21 percent. The stock has been moved at 12.38 percent over the last six months. The stock has performed -1.48
Pfizer Inc. [NYSE: PFE] stock went on a downward path that fall over -0.61% on Friday, amounting to a one-week price increase of more than 2.03%. Over the last 12 months, PFE stock dropped by -11.93%. The one-year Pfizer Inc. stock forecast points to a
Pfizer Inc. [NYSE: PFE] jumped around 0.24 points on Friday, while shares priced at $28.58 at the close of the session, up 0.85%. Compared to the average trading volume of 31.45M shares, PFE reached a trading volume of 28735442 in the most recent trading day,
In the oil sector, in the expectation of an economic rebound in 2021 thanks to anti-Covid-19 vaccinations, optimism has continued to increase costs. In the January Nymex contract, U.S. light crude oil (WTI) rose 0.9 percent to $46.99 a barrel. In February, the Brent contract
The arrangements for coronavirus vaccine programs are well underway on the health front. On Tuesday, the UK distinguished itself by being the first country in the world to approve the use of American Pfizer and its German partner BioNTech’s Covid-19 vaccine. The vaccine will be
On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on Monday, November 23. The market was supported by statements by the British pharmaceutical company AstraZeneca on the potential 90 percent
Copyright © 2024, Powered by Smart TechOne
